BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18243501)

  • 41. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
    Perera AD; Kleymenova EV; Walker CL
    Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.
    Seizinger BR; Rouleau GA; Ozelius LJ; Lane AH; Farmer GE; Lamiell JM; Haines J; Yuen JW; Collins D; Majoor-Krakauer D
    Nature; 1988 Mar; 332(6161):268-9. PubMed ID: 2894613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular genetics of familial renal cell carcinoma syndromes.
    Cohen D; Zhou M
    Clin Lab Med; 2005 Jun; 25(2):259-77. PubMed ID: 15848736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current progress in the diagnosis and treatment of renal cell carcinoma].
    Tsukamoto T; Takahashi A; Kitamura H
    Nihon Jinzo Gakkai Shi; 2002 Dec; 44(8):779-85. PubMed ID: 12607966
    [No Abstract]   [Full Text] [Related]  

  • 46. Genetics of renal cell carcinoma.
    Daniel LN; Linehan WM
    Semin Urol; 1989 Nov; 7(4):258-63. PubMed ID: 2575784
    [No Abstract]   [Full Text] [Related]  

  • 47. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inherited renal cell carcinoma.
    Maher ER
    Br J Urol; 1996 Oct; 78(4):542-5. PubMed ID: 8944511
    [No Abstract]   [Full Text] [Related]  

  • 49. Identification of the genes for kidney cancer.
    Linehan WM
    Cancer Biol Ther; 2006 Jun; 5(6):696-9. PubMed ID: 16775424
    [No Abstract]   [Full Text] [Related]  

  • 50. Re: Percutaneous radio frequency ablation of small renal tumors: initial results.
    Ogan K; Cadeddu JA
    J Urol; 2002 Aug; 168(2):660; author reply 660-1. PubMed ID: 12131338
    [No Abstract]   [Full Text] [Related]  

  • 51. Chronic kidney disease: after nephron reduction, podoctyes get in on the AKT.
    Kirk R
    Nat Rev Nephrol; 2013 Nov; 9(11):624. PubMed ID: 24080798
    [No Abstract]   [Full Text] [Related]  

  • 52. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR.
    Luo L; Wei D; Pan Y; Wang QX; Feng JX; Yu B; Kang T; Luo J; Yang J; Gao S
    Cancer Commun (Lond); 2023 Jul; 43(7):808-833. PubMed ID: 37378422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
    Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
    Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
    Lee SJ; Lattouf JB; Xanthopoulos J; Linehan WM; Bottaro DP; Vasselli JR
    Eur Urol; 2008 Oct; 54(4):845-53. PubMed ID: 18243508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal cancer genetics: von Hippel Lindau and other syndromes.
    Fleming S
    Int J Dev Biol; 1999; 43(5):469-71. PubMed ID: 10535326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Genetic backgrounds of renal cell carcinoma].
    Oya M
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():593-6. PubMed ID: 16523961
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
    Kassouf W
    Eur Urol; 2008 Oct; 54(4):853-4. PubMed ID: 18243501
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.